Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2016; 8(9): 663-672
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.663
Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication
Reina Ohba, Katsunori Iijima
Reina Ohba, Katsunori Iijima, Department of Gastroenterology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
Author contributions: Ohba R performed the research and wrote the manuscript; Iijima K contributed to the critical revision of the manuscript for important intellectual content.
Conflict-of-interest statement: No conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Reina Ohba, MD, PhD, Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Telephone: +81-18-8846573 Fax: +81-18-8017501
Received: March 23, 2016
Peer-review started: March 24, 2016
First decision: May 23, 2016
Revised: June 8, 2016
Accepted: July 14, 2016
Article in press: July 18, 2016
Published online: September 15, 2016
Core Tip

Core tip: Helicobacter pylori (H. pylori) eradication and endoscopic resection appeared to reduce the risk of gastric cancer. However, recent studies show that the risk of metachronous gastric cancer increases in the background of gastric mucosal atrophy even after successful eradication. Thus, curing H. pylori infections may not prevent metachronous gastric cancer in background mucosa with intestinal metaplasia. We review the risk factors and possible approaches for reducing the risk of metachronous gastric cancer.